Published • loading... • Updated
Eurofarma Claims to Lead the Semaglutide Market in Brazil - 28/09/2026 - Panel S.A.
Summary by Folha De S.Paulo
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Eurofarma claims to have won the lead in the market for semiglutide pens - active principle of the Ozempic and Wegovy - in the national mbit, with its medicines Poviztra, used in the treatment against obesity, and Extensior, indicated for the treatment of type 2 diabetes. Read more (09/28/2026)
·São Paulo, Brazil
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
